文献速递银屑病与炎症性皮肤病

生物制剂治疗掌跖脓疱病的药物留存:全国性研究

Drug survival of biologic therapies for palmoplantar pustulosis: A nationwide study.
PubMed 文献 · J Eur Acad Dermatol Venereol · 2023-11-17

该研究纳入2007—2019年丹麦全国前瞻性登记中因掌跖脓疱病(PPP)接受生物制剂治疗的全部患者,共85例患者、194个疗程,分析药物留存情况。全疗法中位停药时间为9.3个月(IQR 3.9–25.6),乌司奴单抗最长为14.6个月(IQR 9.1–51.8)。停药最常见原因为疗效不佳(54.3%),因疗效不佳停药者DLQI评分更高。

要点

  • PPP生物制剂全疗法中位药物留存为9.3个月(IQR 3.9–25.6)。
  • 乌司奴单抗中位停药时间最长,为14.6个月(IQR 9.1–51.8)。
  • 停药最常见原因为疗效不佳(54.3%),其次为不良事件(18.5%)。

核心结论

  • PPP治疗面临显著挑战,无论既往是否使用过生物制剂,各疗法药物留存均有限,乌司奴单抗中位药物留存最长。
  • 因疗效不佳停药的患者DLQI评分更高,提示个体化治疗选择及在确认无效时及时考虑更换治疗的重要性。

研究设计与样本

  • 基于丹麦全国前瞻性登记(2007—2019年)纳入因PPP接受生物制剂治疗的全部患者,共85例患者、194个治疗疗程。
  • 采用描述性统计,药物留存以中位停药时间表示,并用Kaplan-Meier图可视化;按疗程插值绘制DLQI评分轨迹。

主要发现

  • 194个疗程中151个(77.8%)被终止。
  • 终止原因中疗效不佳占54.3%,不良事件占18.5%。
  • 全疗法中位药物留存为9.3个月(IQR 3.9–25.6),乌司奴单抗中位停药时间最长为14.6个月(IQR 9.1–51.8)。
  • 12个月时仍在治疗的比例:生物制剂初治患者中阿达木单抗47.9%、乌司奴单抗64.3%、司库奇尤单抗40.0%。
  • 12个月时仍在治疗的比例:生物制剂经治患者中阿达木单抗58.2%、乌司奴单抗54.5%、司库奇尤单抗51.4%。

关键数值与推荐

  • 全疗法中位药物留存9.3个月(IQR 3.9–25.6)。
  • 乌司奴单抗中位停药时间14.6个月(IQR 9.1–51.8)。
  • 12个月留存率(生物制剂初治):阿达木单抗47.9%、乌司奴单抗64.3%、司库奇尤单抗40.0%。
  • 12个月留存率(生物制剂经治):阿达木单抗58.2%、乌司奴单抗54.5%、司库奇尤单抗51.4%。

临床怎么用

  • 原文结论强调PPP治疗挑战大、各疗法药物留存有限,支持个体化治疗选择并在确认无效时及时考虑更换治疗。

局限性

  • 原文未述局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Biological therapies have established efficacy in psoriasis vulgaris. However, palmoplantar pustulosis (PPP) has proven difficult to treat, and data on drug survival in these patients remain scarce. OBJECTIVE: To investigate drug survival of biological treatments in a nationwide cohort of patients with PPP. METHODS: We included all patients treated for PPP with a biologic from a prospective Danish nationwide registry between 2007 and 2019. Descriptive statistics were reported. Drug survival was calculated for all patients and specified for the most frequently used biologics. Drug survival was reported as median time to discontinuation. Kaplan-Meier plots were used to visualize drug survival. Trajectories of Dermatology Life Quality Index (DLQI) scores were plotted by interpolating between the different visits with a dermatologist for each treatment course. RESULTS: We identified 85 individual patients who received biological therapy for PPP across 194 treatment courses during follow-up. Of the included treatment courses, 151 (77.8%) were discontinued. The most frequent cause of discontinuation was ineffective response to treatment (54.3%), while 18.5% of courses were discontinued due to adverse events. The median drug survival across all therapies for PPP was 9.3 (Inter quartile range (IQR), 3.9-25.6) months. Ustekinumab demonstrated the longest median time to discontinuation of 14.6 (IQR, 9.1-51.8) months. The proportion of bio-naive patients in treatment at 12 months were according to drug 47.9% for adalimumab, 64.3% for ustekinumab and 40.0% for secukinumab. For bio-experienced, it was 58.2% adalimumab, 54.5% for ustekinumab and 51.4% for secukinumab. CONCLUSIONS: The treatment of PPP poses significant challenges, with limited drug survival observed across all therapies regardless of prior experience with biologics. Ustekinumab demonstrated the longest median drug survival. Notably, patients discontinuing therapy due to inefficacy exhibited higher DLQI scores, highlighting the importance of personalized treatment selection and timely consideration of therapy changes when inefficacy is established.

来源:J Eur Acad Dermatol Venereol,查看原文。版权归原作者所有。

引用

  1. Bertelsen T, Egeberg A, Skov L, et al. Drug survival of biologic therapies for palmoplantar pustulosis: A nationwide study. J Eur Acad Dermatol Venereol. 2023. PMID: 37859514. doi:10.1111/jdv.19584

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。